Multisite Evaluation of Phenotypic Mycobacterium tuberculosis Drug Susceptibility Testing Methods Pubblico

Abstract

Drug susceptibility testing (DST) of Mycobacterium tuberculosis (MTB) is crucial in rapidly detecting and eliminating drug resistance. However, phenotypic DST methods have proven difficult to standardize, and previous studies have shown that discordant DST results may occur between and within laboratories based on multiple factors including method, drug, concentration, and genetic mutation(s) present in the isolate. To further investigate this discordance, an expanded Model Performance Evaluation Program (MPEP) study was conducted by the Centers for Disease Control and Prevention (CDC) Division of Tuberculosis Elimination, Laboratory Branch and the Association of Public Health Laboratories (APHL). Thirty MTB isolates previously characterized by CDC DST methods were available, including 8 sets of duplicates. These were sent to a total of 12 public health and clinical laboratories where phenotypic DST was performed by three different methods: indirect agar proportion method, BACTEC™ mycobacterial growth indicator tubes (MGIT) 960™, and Sensititre™ Mycobacterium tuberculosis MIC plate. Molecular detection of drug resistance (MDDR) was also performed by sequencing target loci to detect mutations associated with drug resistance. Site-specific agreement with a growth-based, expected result as well as agreement with a composite result incorporating resistance-conferring mutations was assessed. A Fleiss kappa estimate was calculated in order to measure interlaboratory agreement independent of previous characterization. Agreement was found to vary by site, method, drug, and concentration. Interlaboratory agreement and agreement to the expected, growth-based result was highest for amikacin and kanamycin (range: 0.90 [95% CI: 0.71, 1.00], 1.00 [95% CI: 1.00, 1.00]) and lowest for ethambutol and para-aminosalicylic acid. Agreement with the composite result was worse for rifampin and rifabutin compared to agreement with the expected results, and improved for capreomycin. Many findings were consistent with previously described patterns of discordance, and further supported evidence that discordant results can be observed across multiple methods, drugs, and strains.

Table of Contents

Chapter I: Background   …………………………………………………            1

Chapter II: Manuscript                                                                          

Introduction      ………………………………………………………………             19

Materials and Methods ………………………………………………….              21

Results ……………………………………………………………………………              28

Discussion          ………………………………………………………………            39                                      

References         ………………………………………………………………             54

Tables   ……………………………………………………………………………              65-71

 

Figures & Figure Legends             ………………………………………          72-80    

 

About this Master's Thesis

Rights statement

• Permission granted by the author to include this thesis or dissertation in this repository. All rights reserved by the author. Please contact the author for information regarding the reproduction and use of this thesis or dissertation.

School	Rollins School of Public Health
Department	Epidemiology
Subfield / Discipline	Epidemiology - MPH & MSPH
Degree	M.P.H.
Submission	Master's Thesis
Language	English
Research Field	Health Sciences, Public Health
Parola chiave	Mycobacterium tuberculosis antituberculosis drugs interlaboratory agreement drug resistance drug susceptibility testing mulitsite evaluation tuberculosis
Committee Chair / Thesis Advisor	Castro, Kenneth, Emory University
Committee Members	Starks, Angela, CDC
Partnering Agencies	CDC

Ultima modifica

Primary PDF

Thumbnail	Title	Date Uploaded	Actions
	Multisite Evaluation of Phenotypic Mycobacterium tuberculosis Drug Susceptibility Testing Methods ()	2018-04-25 15:10:04 -0400	Press to Select an action Download

Supplemental Files

Thumbnail	Title	Date Uploaded	Actions